Cytosorbents Corporation
CTSO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $9 | $10 | $9 | $9 |
| % Growth | -1.4% | 10.2% | -4.6% | – |
| Cost of Goods Sold | $3 | $3 | $3 | -$0 |
| Gross Profit | $7 | $7 | $6 | $9 |
| % Margin | 70.3% | 70.9% | 71.1% | 102.7% |
| R&D Expenses | $1 | $1 | $2 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $9 | $0 | $0 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $9 | $8 | $3 |
| Operating Expenses | $10 | $10 | $10 | $13 |
| Operating Income | -$3 | -$4 | -$4 | -$4 |
| % Margin | -30.2% | -37.6% | -44.5% | -44.2% |
| Other Income/Exp. Net | -$1 | $6 | $2 | -$6 |
| Pre-Tax Income | -$4 | $2 | -$1 | -$10 |
| Tax Expense | -$0 | $0 | $0 | -$2 |
| Net Income | -$3 | $2 | -$1 | -$8 |
| % Margin | -33.4% | 20.2% | -16.9% | -86.2% |
| EPS | -0.05 | 0.031 | -0.024 | -0.14 |
| % Growth | -260.8% | 228% | 82.6% | – |
| EPS Diluted | -0.05 | 0.029 | -0.024 | -0.14 |
| Weighted Avg Shares Out | 63 | 63 | 61 | 55 |
| Weighted Avg Shares Out Dil | 63 | 67 | 61 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$4 | -$9 |
| % Margin | -30.8% | -33.4% | -40.3% | -93.2% |